Prior studies found high prevalence of respiratory diseases in IgE-deficient patients (IgE<2.5 kU/L). The utility of allergen-specific testing in these patients is unknown. We investigated skin and serum specific IgE (ssIgE) test positivity to environmental allergens in patients with IgE-deficiency. METHODS: IgE-deficient patients with rhinitis and/or asthma diagnoses who had skin prick testing (SPT), intradermal skin testing (IDST) and/or ssIgE done (2010-2018) were randomly matched (age and gender) to three groups of patients with rhinitis and/or asthma who had environmental testing during the same period: normal IgE (2.5≤IgE<100), high IgE (100≤IgE<1000), very high IgE levels (≥1000 kU/L). RESULTS: Out of 71 IgE-deficient patients identified, 21 (30%) had at least one positive skin test, compared with 69% of patients with normal (p<0.05), 94% with high (p<0.05) and 93% (p<0.05) with very high IgE levels. In IgE-deficient individuals, SPT identified at least one sensitization in 14/71 (20%) patients (mean of 364 positive SPT/patient), IDST in 11/37 (15.5%) patients and ssIgE were positive (ssIgE>0.1 kU/L) in 2/52 (3.8%) individuals. The proportion of patients being on subcutaneous immunotherapy (IT) was 4.2% in the IgE-deficiency group, similar with the rate of IT in individuals with normal IgE levels (5.6%, p50.7) and significantly lower than in those with high (19.7%, p<0.01) and very high IgE levels (22.9%, p<0.01). CONCLUSIONS: Although IgE-deficient patients lack serum IgE, about a third of those with respiratory symptoms have positive skin testing. Allergen-specific tests are useful to diagnose environmental sensitizations and prescribe immunotherapy in IgE-deficient individuals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.